NOXXON Pharma AG, a Berlin, Germany-based company focused on the development of mirror image oligonucleotide therapeutics, closed a €33m Series D round of financing.The round was led by new investor NGN Capital, with participation from existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.
The funds raised will be used for the ongoing clinical and pre-clinical development of the company´s lead products NOX-E36, NOX-A12, and NOX-H94 in the fields of diabetic complications, oncology and hematology.
These products are inhibitors of their respective targets, generated with NOXXON’s proprietary Spiegelmer® technology.
FinSMEs
27/05/2010